Goldman Sachs analyst Scott Fidel assumed coverage of Tenet Healthcare (THC) with a Buy rating and $224 price target The firm sees favorable trends continuing for the hospital sector through 2028, including supportive labor dynamics, tailwinds from previously approved pro-utilization government policies, and the industry showing more effective adaptation to structural changes. However, the sector will face new pressures from implementation of the One Big Beautiful Bill, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $225 from $205 at KeyBanc
- Tenet Healthcare price target raised to $238 from $200 at Wells Fargo
- Tenet Healthcare price target raised to $229 from $208 at Barclays
- Tenet Healthcare price target raised to $225 from $205 at BofA
- Tenet Healthcare’s Strategic Positioning and Growth Potential Justify Buy Rating